Thirty rare cases of hemorrhage have been reported in Britain for more than 18 million people who have received the AstraZeneca vaccine, the national medical director said on Friday.
“The benefits of the Covid-19 vaccine continue to outweigh any risks,” said Medicines and Healthcare products Regulatory Agency (MHRA), urging the public to continue taking the vaccine.
As of March 24, reports of 22 cases of cerebral venous sinus thrombosis (CVST) and eight other cases of other low-density blood vessels were reported.
“The risk of having this special type of blood is very small,” the agency said.
“The number and nature of suspected adverse reactions reported so far is not uncommon compared to other commonly used vaccines,” the MHRA online statement said.
However, there were no such reports of the Pfizer / Biotech vaccine.
The organization said vaccination was the most effective way to reduce the number of deaths and serious illnesses caused by coronavirus.
The Netherlands on Friday was the latest in a line of European countries to set targets for the AstraZeneca jab for people under 60 amid fears of a blood clot.
The move comes after five new cases in the Netherlands involved women between the ages of 25 and 65, one of whom died.
Germany also made a similar decision earlier this week.
The European Medicines Agency (EMA), which also announced that AstraZeneca vaccine is safe, such as the World Health Organization, is expected to announce revised recommendations on the issue on April 7.
The EMA also said on Wednesday it believed the vaccine was safe and that experts had not identified any risk factors such as age, gender or medical history.
Britain, where the vaccine was vaccinated with the University of Oxford, became one of the countries most affected by coronavirus, with an estimated 127,000 deaths.
